Atty Docket No. 056001-02943

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listing, of claims in the application:

Listing of Claims:

1. (Original) A hepatocyte cell culture comprising liver cells in a bioreactor for use in a liver assist device comprising one or more hepatocytes having increased detoxification enzyme activity.

wherein the hepatocytes are isolated from a liver of a mammalian donor that had been administered at least one induction agent prior to isolation of the hepatocytes,

wherein the induction agent is selected from the group consisting of: betanaphthoflavone, phenobarbital, 3-methylcholanthrene, ethanol, dexamethasone,
arochlor 1254, 2,3,7,8-tetrachlorodibenzo-p-dioxin, phenothiazine,
chlorpromazine, isosafole, γ-chlordane, allylisopropylacetamide, wans-stilbene
oxide, kepone, acetone, isoniazid, pyridine, pyrazole, 4-methylpryrazole,
pregnenolone 16α-carbonitrile, troleandomycin, clotrimazole, closibrate,
clobuzarit, di(2-ethylexyl)phthalate, and mono-(2-ethylhexyl)phthalate.

- 2. (Original) The hepatocyte cell culture of claim 1, wherein the induction agent is phenobarbital and wherein the thus induced hepatocytes have a functional cytochrome P450 isozyme activity on BROD substrates which is about 20 to about 100-fold greater than hepatocytes isolated from a mammalian donor that was not administered an induction agent.
- 3. (Original) The hepatocyte cell culture of claim 1, wherein the induction agent is phenobarbital and wherein the thus induced hepatocytes have a functional cytochrome P450

3

Atty Docket No. 056001-02943

isozyme activity on PROD substrates which is about 2 to about 40-fold greater than hepatocytes isolated from a mammalian donor that was not administered an induction agent.

- 4. (Original) The hepatocyte cell culture of claim 1, wherein the induction agent is phenobarbital and wherein the thus induced hepatocytes have a functional cytochrome P450 isozyme activity on 7-ethoxycoumarin substrates which is about 20 to about 50-fold greater than hepatocytes isolated from a mammalian donor that was not administered an induction agent.
- 5. (Original) The hepatocyte cell culture of claim 1, wherein the induction agent is phenobarbital and wherein the thus induced hepatocytes have a functional cytochrome P450 isozyme activity on lidocaine which is about 10 to about 20-fold greater than hepatocytes isolated from a mammalian donor that was not administered an induction agent.
- 6. (Original) The hepatocyte cell culture of claim 1, wherein the induction agent is phenobarbital and wherein the thus induced hepatocytes have a functional cytochrome P450 isozyme activity on lidocaine which is about 20 to about 50-fold greater than hepatocytes isolated from a mammalian donor that was not administered an induction agent.
- 7. (Original) The hepatocyte cell culture of claim 1, wherein the induction agent is betanaphthoflavone and wherein the thus induced hepatocytes have a functional cytochrome P450 isozyme activity on MROD substrates which is about 2 to about 10-fold greater than hepatocytes isolated from a mammalian donor that was not administered an induction agent.
- 8. (Original) The hepatocyte cell culture of claim 1, wherein the induction agent is betanaphthoflavone and wherein the thus induced hepatocytes have a functional cytochrome P450 isozyme activity on EROD substrates which is about 2 to about 10-fold greater than hepatocytes isolated from a mammalian donor that was not administered an induction agent.

Atty Docket No. 056001-02943

- 9. (Original) The hepatocyte cell culture of claim 1, wherein the induction agent is 3-methylcholanthrene and wherein the thus induced hepatocytes have a functional cytochrome P450 isozyme activity on PROD substrates which is about 2 to about 10-fold greater than hepatocytes isolated from a mammalian donor that was not administered an induction agent.
- 10. (Original) The hepatocyte cell culture of claim 1, wherein the induction agent is 3-methylcholanthrene and wherein the thus induced hepatocytes have a functional cytochrome P450 isozyme activity on MROD substrates which is about 2 to about 10-fold greater than hepatocytes isolated from a mammalian donor that was not administered an induction agent.
- 11. (Original) The hepatocyte cell culture of claim 1, wherein the induction agent is 3-methylcholanthrene and wherein the thus induced hepatocytes have a functional cytochrome P450 isozyme activity on EROD substrates which is about 10 to about 20-fold greater than hepatocytes isolated from a mammalian donor that was not administered an induction agent.
- 12. (Original) The hepatocyte cell culture of claim 1, wherein the induction agent is 3-methylcholanthrene and wherein the thus induced hepatocytes have a functional cytochrome P450 isozyme activity on diazepam substrates which is about 2 to about 10-fold greater than hepatocytes isolated from a mammalian donor that was not administered an induction agent.
 - 13, (Currently Amended) A bioreactor comprising:
 - a bioreactor chamber comprising a first region and a second region;
- a gas-permeable, liquid impermeable membrane defining said first region and said second region of said bioreactor chamber; and

hepatocytes having increased detoxification enzyme activity,

wherein the hepatocytes are isolated from a liver of a mammalian donor that had been administered at least one induction agent prior to isolation of hepatocytes,

Atty Docket No. 056001-02943

wherein the induction agent is selected from the group consisting of beta-naphthoflavone, phenobarbital, 3-methylcholanthrene, ethanol, dexamethasone, arochlor 1254, 2.3,7,8-tetrachlorodibenzo-p-dioxin, phenothiazine, chlorpromazine, isosafole, γ-chlordane, allylisopropylacetamide, trans-stilbene oxide, kepone, acetone, isoniazid, pyridine, pyrazole, 4-methylpryrazole, pregnenolone 16α-carbonitrile, troleandomycin, clotrimazole, clofibrate, clobuzarit, di(2-ethylexyl)phthalate, and mono-(2-ethylhexyl)phthalate;

wherein the bioreactor can be used in a liver assist device.

6